Sacubitril: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
<scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH LBQ657 (Sacubitrilat)</scene> ([[5jmy]]). | <scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH LBQ657 (Sacubitrilat)</scene> ([[5jmy]]). | ||
<scene name='10/1001143/Binding_site/1'>Sacubitrilat binding site</scene>. | <scene name='10/1001143/Binding_site/1'>Sacubitrilat binding site</scene>. Water molecules are shown as red spheres. | ||
<scene name='10/1001143/Zn_coord/1'>Zn coordination site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 11:21, 15 October 2023
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also Sacubitril. (5jmy). . Water molecules are shown as red spheres. .
|
| ||||||||||